Home / Companies / Otsuka Pharmaceutical Development & Commercialization, Inc.

Otsuka Pharmaceutical Development & Commercialization, Inc.

FDA Regulatory Profile

Summary

Total Recalls
2
510(k) Clearances
0
Inspections
16
Compliance Actions
0

Recent Recalls

NumberClassProductDate
D-0018-2019Class IIItreatNOW ABILIFY (aripiprazole) / ABILIFY MAINTENA 400-mg (aripiprazole) for extended release injectSeptember 17, 2018
D-0017-2019Class IIItreatNOW ABILIFY (aripiprazole) and ABILIFY MAINTENA (aripiprazole) 400MG for extended release injecSeptember 17, 2018